

## NEW ZEALAND DATA SHEET

### 1. PRODUCT NAME

Perjeta 420 mg concentrate for solution for infusion.

### 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Perjeta is supplied as a single-use vial containing 14 mL of preservative-free concentrate solution. Each vial contains 420 mg of pertuzumab (30 mg/mL) with the following excipients: sucrose, polysorbate 20, histidine and acetic acid, glacial.

Perjeta is a recombinant humanized monoclonal antibody. The antibody is based upon the human IgG1 kappa framework sequence, with a molecular weight of ~ 148kDa and composed of two light chains consisting of 214 amino acid residues and two heavy chains consisting of 448 or 449 amino acid residues.

### 3. PHARMACEUTICAL FORM

Concentrate for solution for infusion.

Clear to opalescent, colourless to slightly brownish solution.

### 4. CLINICAL PARTICULARS

#### 4.1 Therapeutic indications

##### *Early Breast Cancer*

Perjeta is indicated in combination with trastuzumab and chemotherapy for the:

- neoadjuvant treatment of patients with HER2-positive, early stage (either > 2 cm in diameter or node positive), inflammatory or locally advanced breast cancer as part of a complete treatment regimen for early breast cancer
- adjuvant treatment of patients with HER-2 positive early breast cancer at high risk of recurrence.

##### *Metastatic Breast Cancer*

Perjeta is indicated in combination with trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for their metastatic disease.

#### 4.2 Dose and Method of Administration

##### *General*

Substitution by any other biological medicinal product requires the consent of the prescribing physician. In order to prevent medication errors, it is important to check the vial labels to ensure that the drug being prepared and administered is Perjeta.

DO NOT ADMINISTER PERJETA AS AN IV PUSH OR BOLUS.

### ***Detection of HER2 Protein Overexpression or HER2 Gene Amplification***

Patients can only be treated with Perjeta in combination with trastuzumab and must have a HER2-positive tumour status, defined as a score of 3+ by immunohistochemistry (IHC) or a ratio of  $\geq 2.0$  by in situ hybridization (ISH).

To ensure accurate and reproducible results, the testing must be performed in a specialised laboratory, which can ensure validation of the testing procedures.

HER2 protein overexpression should be detected using an IHC-based assessment of fixed tumour blocks. HER2 gene amplification should be detected using ISH of fixed tumour blocks. Examples of ISH include fluorescence in situ hybridization (FISH), chromogenic in situ hybridization (CISH) and silver in situ hybridization (SISH).

For any other method to be used for the assessment of HER2 protein or gene expression, the test method must be precise and accurate enough to demonstrate overexpression of HER2 (it must be able to distinguish between moderate (congruent with 2+) and strong (congruent with 3+) HER2 overexpression).

For full instructions on assay performance and interpretation please refer to the package inserts of validated HER2 testing assays. Official recommendations on HER2 testing may also apply.

### ***Metastatic and Early Breast Cancer***

The recommended initial dose of Perjeta is 840 mg, administered as a 60 min IV infusion, followed by, every 3 weeks, a 420 mg dose administered over 30-60 min. An observation period of 30-60 minutes is recommended after completion of each Perjeta infusion. The observation period should be completed prior to any subsequent infusion of trastuzumab or chemotherapy (see 4.4 Special warnings and precautions for use).

Perjeta and trastuzumab should be administered sequentially and can be given in any order. When trastuzumab is administered with Perjeta, the recommendation is to follow a 3-weekly schedule, administered as an IV infusion, with an initial trastuzumab dose of 8 mg/kg followed by every 3 weeks, a dose of 6 mg/kg body weight, or a fixed dose of trastuzumab subcutaneous (SC) injection (600mg) for the initial dose and every 3 weeks thereafter irrespective of the patient's body weight.

In patients receiving a taxane, Perjeta and trastuzumab should be administered prior to the taxane. When docetaxel is administered with Perjeta, the recommended initial docetaxel dose is 75 mg/m<sup>2</sup>.

In patients receiving an anthracycline-based regimen, Perjeta and trastuzumab should be administered following completion of the entire anthracycline regimen.

### ***Duration of Treatment***

#### **Metastatic Breast cancer (MBC)**

Perjeta should be administered in combination with trastuzumab and docetaxel until disease progression or unmanageable toxicity. Treatment with Perjeta and trastuzumab may continue even if treatment with docetaxel is discontinued.

### Early Breast cancer (EBC)

In the neoadjuvant setting (before surgery), it is recommended that patients are treated with Perjeta for three to six cycles depending on the regimen chosen in combination with trastuzumab and chemotherapy (see 5.1 Pharmacodynamic properties).

In the adjuvant setting (after surgery), Perjeta should be administered in combination with trastuzumab for a total of one year (maximum 18 cycles or until disease recurrence, or unmanageable toxicity, whichever occurs first), as part of a complete regimen for early breast cancer, including standard anthracycline and/or taxane-based chemotherapy. Perjeta and trastuzumab should start on Day 1 of the first taxane-containing cycle and should continue even if chemotherapy is discontinued (see 5.1 Pharmacodynamic properties).

Patients who start Perjeta and trastuzumab in the neoadjuvant setting should continue to receive adjuvant Perjeta and trastuzumab to complete 1 year of treatment.

### ***Dose Modifications***

Perjeta should be discontinued if trastuzumab treatment is discontinued.

Dose reductions are not recommended for Perjeta.

Trastuzumab dose reductions are not recommended (see trastuzumab prescribing information).

For chemotherapy dose modifications, see the prescribing information for each agent.

### ***Infusion-related reactions***

The infusion rate of Perjeta may be slowed or the administration interrupted if the patient develops an infusion-associated reaction.

### ***Hypersensitivity reactions/anaphylaxis***

The infusion should be discontinued immediately and permanently if the patient experiences a serious hypersensitivity reaction (e.g. anaphylaxis) (see 4.4 Special warnings and precautions for use).

### ***Left ventricular dysfunction***

See 4.4 Special warnings and precautions for use for information on dose recommendations in the event of left ventricular dysfunction.

### **Special populations**

*Elderly:* No dose adjustment is required in the elderly population ( $\geq 65$  years of age) (see 4.4 Special warnings and precautions for use).

*Children:* The safety and efficacy of Perjeta in children and adolescents below 18 years of age have not been established.

*Renal impairment:* Dose adjustments of Perjeta are not needed in patients with mild or moderate renal impairment. No dose recommendations can be made for patients with severe renal impairment because of the limited pharmacokinetic data available (see 5.2 Pharmacokinetic properties).

**Hepatic impairment:** The safety and efficacy of Perjeta have not been studied in patients with hepatic impairment.

***Delayed or missed doses***

For recommendations on delayed or missed doses, please refer to Table 1 below.

**Table 1: Recommendations regarding delayed or missed doses.**

| Time between two sequential doses | Perjeta   | Trastuzumab  |   |
|-----------------------------------|---|--|---|
|                                   |   | IV   | SC  |
| < 6 weeks                         | The 420 mg dose of Perjeta IV should be administered as soon as possible. Do not wait until the next planned dose.  | The 6 mg/kg dose of trastuzumab IV should be administered as soon as possible. Do not wait until the next planned dose.  | The fixed dose of 600mg trastuzumab SC should be administered as soon as possible. Do not wait until the next planned dose. |
| ≥ 6 weeks                         | The loading dose of 840 mg Perjeta IV should be re-administered as a 60 minute infusion, followed by a maintenance dose of 420 mg IV administered over a period of 30 to 60 minutes every 3 weeks thereafter. | The loading dose of 8 mg/kg of trastuzumab IV should be re-administered over approximately 90 minutes, followed by a maintenance dose of 6 mg/kg IV administered over a period of 30 or 90 minutes every 3 weeks thereafter. |   |

***Instructions for dilution***

Perjeta should be prepared by a healthcare professional using aseptic technique.

***Initial dose***

Dilute 28 mL (two vials, 840mg) of Perjeta in 250 mL 0.9% sodium chloride (do not withdraw saline out of the infusion bag). After dilution, the solution should contain approximately 3.0 mg/mL of pertuzumab.

***Subsequent doses***

Dilute 14 mL (one vial, 420 mg) of Perjeta in 250 mL 0.9% sodium chloride (do not withdraw saline out of the infusion bag). After dilution, the solution should contain approximately 1.6 mg/mL of pertuzumab.

Glucose (5%) solution should not be used (see 6.2 Incompatibilities).

The bag should be *gently* inverted to mix the solution in order to avoid foaming.

Parenteral drug products should be inspected visually for particulates and discoloration prior to administration.

Perjeta is for single use in one patient only. Once the infusion is prepared it should be administered immediately (see 6.3 Shelf-life).

### **4.3 Contraindications**

Perjeta is contraindicated in patients with known hypersensitivity to pertuzumab, chinese hamster ovary cell proteins or to any other component of the product.

### **4.4 Special warnings and precautions for use**

#### ***General***

Perjeta therapy should only be administered under the supervision of a healthcare professional experienced in the treatment of cancer patients. Perjeta must be diluted by a healthcare professional and administered as an IV infusion.

In order to improve traceability of biological medicinal products, the trade name and the batch number of the administered product should be clearly recorded in the patient medical record.

#### ***Cardiac Failure and left ventricular dysfunction***

Decreases in left ventricular ejection fraction (LVEF) have been reported with drugs that block HER2 activity, including Perjeta.

Close clinical and regular radiological monitoring of cardiac function is recommended and any decision regarding commencing Perjeta in patients with cardiac risk factors should be balanced against the risk of possible cardiac dysfunction and necessitating discontinuation of therapy.

Perjeta was associated with an increased risk of left ventricular dysfunction (LVD) in the NEOSPHERE and TRYPHAENA studies. Up to 16% of patients developed LVD in the arm receiving FEC followed by Perjeta plus trastuzumab and docetaxel in the TRYPHAENA study. Congestive heart failure necessitating discontinuation of therapy occurred in a patient with pre-existing cardiac risk factors receiving concurrent neoadjuvant Perjeta and trastuzumab without chemotherapy in the NEOSPHERE study.

The incidence of symptomatic left ventricular dysfunction (LVD[congestive heart failure]) was higher in patients treated with Perjeta in combination with trastuzumab and chemotherapy compared with trastuzumab and chemotherapy. Patients who have received prior anthracyclines or prior radiotherapy to the chest area may be at higher risk of decreased LVEF. The majority of cases of symptomatic heart failure reported in the adjuvant setting were in patients who had received anthracycline-based chemotherapy (see 4.8 Undesirable effects).

Perjeta has not been studied in patients with a baseline LVEF value of  $\leq 50\%$ ; a prior history of congestive heart failure (CHF); decreases in LVEF to  $< 50\%$  during prior trastuzumab adjuvant therapy; conditions that could impair left ventricular function such as uncontrolled hypertension, recent myocardial infarction, serious cardiac arrhythmia requiring treatment or a cumulative prior anthracycline exposure to  $> 360\text{mg/m}^2$  of doxorubicin (or its equivalent).

Assess LVEF prior to initiation of Perjeta and at regular intervals during treatment to ensure that LVEF is within normal limits (see Table 2 below). If the LVEF declines as indicated in Table 2 and has not improved, or has declined further at the subsequent assessment, discontinuation of Perjeta and trastuzumab should be strongly considered, unless the benefits for the individual patient are deemed to outweigh the risks.

**Table 2 – Dose Recommendations for Left Ventricular Dysfunction**

|                                 | <b>Pre-treatment LVEF:</b> | <b>Monitor LVEF every:</b>                  | <b>Withhold PERJETA and trastuzumab for at least 3 weeks for an LVEF decrease to:</b> | <b>Resume PERJETA and trastuzumab after 3 weeks if LVEF has recovered to:</b> |
|---------------------------------|----------------------------|---|---|---|
| <b>Metastatic Breast Cancer</b> | ≥50%                       | ~ 12 weeks                                  | Either  |   |
|                                 |                            |   | <40%  | 40%-45% with a fall of ≥ 10% points below pre-treatment value                 |
| <b>Early Breast Cancer</b>      | ≥55%*                      | ~ 12 week (once during neoadjuvant therapy) | <50% with a fall of ≥10% points below pre-treatment value                             |   |
|                                 |                            |   | ≥50%  | < 10% points below pre-treatment value  |

\*for patients receiving anthracycline-based chemotherapy, a LVEF of ≥ 50% is required after completion of anthracyclines before starting PERJETA and trastuzumab

### ***Infusion-related reactions***

Perjeta has been associated with infusion-related reactions, including events with fatal outcomes (see 4.8 Undesirable effects). Close observation of the patient during, and for 60 min after the first infusion and during, and for 30 min following subsequent infusions, is recommended following the administration of Perjeta. If a significant infusion related reaction occurs, the infusion should be slowed down or interrupted and appropriate medical therapies should be administered. Patients should be evaluated and carefully monitored until complete resolution of signs and symptoms. Permanent discontinuation should be considered in patients with severe infusion reactions. This clinical assessment should be based on the severity of the preceding reaction and response to administered treatment for the adverse reaction (see 4.2 Dose and Method of Administration).

### ***Hypersensitivity reactions/anaphylaxis***

Patients should be observed closely for hypersensitivity reactions. Severe hypersensitivity reactions, including anaphylaxis and events with fatal outcomes have been observed in patients treated with Perjeta (see 4.8 Undesirable effects). Medications to treat such reactions, as well as emergency equipment, should be available for immediate use. Perjeta is contraindicated in patients with known hypersensitivity to pertuzumab or to any Perjeta excipients (see 4.3 Contraindications).

### ***Febrile neutropenia***

Patients treated with Perjeta, trastuzumab and docetaxel are at increased risk of febrile neutropenia compared with patients treated with placebo, trastuzumab and docetaxel. This may be associated with a higher incidence of mucositis and diarrhoea in Perjeta-treated patients. In the CLEOPATRA study, in both treatment groups, the proportion of patients experiencing febrile neutropenia was highest in the first cycle of therapy and declined steadily thereafter. An increased incidence of febrile neutropenia was observed for Asian patients in both treatment groups compared with patients of other races and from other geographic regions. In the CLEOPATRA study, among Asian patients, the incidence of febrile neutropenia was 26% in the Perjeta-treated group compared with 12% in the placebo-treated group. If treatment is necessary, it should be administered in accordance with local guidelines, and administration of colony-stimulating factors (G-CSF) should be considered. Any signs of concomitant infection should be treated as appropriate.

### ***Tumour Lysis Syndrome***

Tumour Lysis Syndrome (TLS) refers to the constellation of metabolic disturbances that may be seen after initiation of effective cancer treatment. It usually occurs in patients with high grade, bulky, rapidly proliferating, treatment-responsive tumours and in patients with acute haematological malignancies.

To date, while no cases have been reported from controlled investigational clinical trials in more than 10,000 patients exposed to Perjeta cases suggestive of TLS have been reported in the postmarketing setting. There is no confirmed causal association between TLS and Perjeta in these cases, however patients at risk of tumour lysis syndrome should be monitored closely and appropriate precautions taken.

### ***Use in renal impairment***

The safety and efficacy of Perjeta have not been studied in patients with renal impairment.

### ***Use in hepatic impairment***

The safety and efficacy of Perjeta have not been studied in patients with hepatic impairment.

### ***Paediatric use***

The safety and efficacy of Perjeta in children and adolescents below 18 years of age have not been established.

### ***Use in the elderly***

No overall differences of safety and efficacy of Perjeta were observed in patients  $\geq 65$  and  $< 65$  years of age with the exception of diarrhoea, which had an observed increase in incidence in patients  $\geq 65$  years of age (see 4.2 Dose and Method of Administration).

### ***Effect on laboratory tests***

No text.

## **4.5 Interaction with other medicines and other forms of interaction**

A sub-study in 37 patients in the pivotal trial CLEOPATRA showed no evidence of drug-drug interaction between pertuzumab and trastuzumab and between pertuzumab and docetaxel. In

addition, no clinically relevant pharmacokinetic interaction of co-administered docetaxel or trastuzumab on pertuzumab was evident based on the population pharmacokinetics analysis. This lack of drug-drug interaction was confirmed by pharmacokinetic data from the NEOSPHERE and APHINITY studies.

Five studies evaluated the effects of pertuzumab on the pharmacokinetics of co-administered cytotoxic agents; docetaxel, paclitaxel, gemcitabine, capecitabine, carboplatin and erlotinib. There was no evidence of any pharmacokinetics interaction between pertuzumab and any of these agents. The pharmacokinetics of pertuzumab in these studies was comparable to those observed in single-agent studies.

#### **4.6 Fertility, pregnancy and lactation**

**Contraception:** Women of child bearing potential, including those who are partners of male patients should use effective contraception while receiving Perjeta and for 6 months following the last dose of Perjeta.

##### ***Use in pregnancy – Category D***

Perjeta should be avoided during pregnancy unless the potential benefit for the mother outweighs the potential risk to the foetus.

There are no studies of Perjeta in pregnant women. Reproductive toxicology studies have been conducted in cynomolgus monkeys at loading doses of 30 to 150 mg/kg and maintenance doses of 10 to 100 mg/kg achieving plasma pertuzumab concentrations approximately 2-19 times the clinical C<sub>max</sub> at the loading dose of 800 mg. IV administration of pertuzumab from Gestation Day (GD) 19 through 50 (period of organogenesis) was shown to be embryo- and foetotoxic with a dose dependent increase in embryo-foetal deaths and abortions between GD 25 to 70. Delayed renal development, oligohydramnios, and other abnormalities were identified at GD100. Therefore, based on these animal studies and the mechanism of action, Perjeta is considered to have the potential to cause foetal harm when administered to a pregnant woman.

**Labour and delivery:** The safe use of Perjeta during labor and delivery has not been established.

##### ***Use in lactation***

Because human IgG is secreted in human milk, and the potential for absorption and harm to the infant is unknown, a decision should be made to discontinue nursing or Perjeta taking into account the importance to the mother and the elimination half-life of pertuzumab (see 5.2 Pharmacokinetic properties).

#### **4.7 Effects on ability to drive and use machines**

No studies on the effects on the ability to drive and to use machines have been performed.

#### **4.8 Undesirable effects**

The safety of Perjeta has been evaluated in more than 6000 patients in Phase I-III trials in patients with various malignancies and predominantly treated with Perjeta in combination with other anti-neoplastic agents. Those studies included the pivotal trials CLEOPATRA (n=808), NEOSPHERE (n=417), TRYPHAENA (n=225), and APHINITY (n=4804) (pooled in Table 3). The safety of Perjeta was generally consistent across studies, although the incidence and



most common adverse drug reactions (ADRs) varied depending on whether Perjeta was administered as monotherapy or in combination with other anti-neoplastic agent(s).

### ***Metastatic and Early Breast Cancer***

Table 3 summarizes the ADRs from the Perjeta-treatment arms of the following pivotal clinical trials:

- CLEOPATRA, in which Perjeta was given in combination with trastuzumab and docetaxel to patients with MBC (n=453)
- NEOSPHERE (n=309) and TRYPHAENA (n=218), in which neoadjuvant Perjeta was given in combination with trastuzumab and chemotherapy to patients with locally advanced, inflammatory or EBC
- APHINITY, in which adjuvant Perjeta was given in combination with trastuzumab and anthracycline-based or non-anthracycline-based, taxane-containing chemotherapy to patients with EBC (n=2364)

As Perjeta is used with trastuzumab and chemotherapy, it is difficult to ascertain the causal relationship of an adverse reaction to a particular drug.

The following categories of frequency have been used: very common ( $\geq 1/10$ ), common ( $\geq 1/100$  to  $< 1/10$ ), uncommon ( $\geq 1/1,000$  to  $< 1/100$ ), rare ( $\geq 1/10,000$  to  $< 1/1000$ ), very rare ( $< 1/10,000$ ).

The most common ADRs ( $\geq 30\%$ ) from this pooled data were diarrhoea, alopecia, nausea, fatigue, neutropenia, and vomiting. The most common NCI-CTCAE Grade 3-4 ADRs ( $\geq 10\%$ ) were neutropenia and febrile neutropenia.

**Table 3 – Summary of ADRs in patients treated with Perjeta <sup>^</sup>**

| ADR<br>(MedDRA Preferred Term)<br><br>System Organ Class | Perjeta<br>+ trastuzumab<br>+ chemotherapy <sup>^^</sup><br><br>n = 3344 <sup>^^</sup> (100%)<br><br>Frequency rate % |                 | Frequency<br>category |
|--|---|-----------------|-----------------------|
|  | All Grades<br>%   | Grades 3-4<br>% |                       |
| <b>Blood and lymphatic system disorders</b>              |   |                 |                       |
| Neutropenia  | 31.4  | 24.2            | Very common           |
| Anaemia  | 24.8  | 5.7             | Very common           |
| Leukopenia   | 10.8  | 6.1             | Very common           |
| Febrile neutropenia*                                     | 11.9  | 11.8            | Very common           |
| <b>Cardiac disorders</b>                                 |   |                 |                       |
| Left ventricular dysfunction**                           | 1.4   | 0.3             | Common                |
| Cardiac failure congestive**                             | 0.1   | <0.1            | Uncommon              |
| <b>Eye disorders</b>                                     |   |                 |                       |
| Lacrimation increased                                    | 12.1  | -               | Very common           |
| <b>Gastrointestinal disorders</b>                        |   |                 |                       |

| ADR<br>(MedDRA Preferred Term)<br><br>System Organ Class        | Perjeta<br>+ trastuzumab<br>+ chemotherapy <sup>^^</sup><br><br>n = 3344 <sup>^^</sup> (100%)<br><br>Frequency rate % |                 | Frequency<br>category |
|---|---|-----------------|-----------------------|
|   | All Grades<br>%   | Grades 3-4<br>% |                       |
| Diarrhoea   | 67.9  | 8.9             | Very common           |
| Nausea  | 60.8  | 1.9             | Very common           |
| Vomiting  | 30.0  | 1,7             | Very common           |
| Stomatitis  | 24.9  | 1.6             | Very common           |
| Constipation  | 24.5  | 0.4             | Very common           |
| Dyspepsia   | 13.2  | <0.1            | Very common           |
| Abdominal pain  | 11.7  | 0.4             | Very common           |
| <b>General disorders and<br/>administration site conditions</b> |   |                 |                       |
| Fatigue   | 44.3  | 3.3             | Very common           |
| Mucosal inflammation  | 23.2  | 1.5             | Very common           |
| Asthenia  | 20.9  | 1.5             | Very common           |
| Pyrexia   | 18.9  | 0.6             | Very common           |
| Oedema peripheral   | 16.2  | <0.1            | Very common           |
| <b>Immune system disorders</b>                                  |   |                 |                       |
| Drug hypersensitivity   | 2.5   | 0.4             | Common                |
| Hypersensitivity  | 3.3   | 0.4             | Common                |
| <b>Infections and infestations</b>                              |   |                 |                       |
| Upper respiratory tract infection                               | 9.5   | 0.3             | Common                |
| Nasopharyngitis   | 12.8  | <0.1            | Very common           |
| Paronychia  | 3.9   | <0.1            | Common                |
| <b>Metabolism and nutrition<br/>disorders</b>                   |   |                 |                       |
| Decreased appetite  | 23.1  | 0.8             | Very common           |
| <b>Musculoskeletal and connective<br/>tissue disorders</b>      |   |                 |                       |
| Myalgia   | 24.3  | 0.8             | Very common           |
| Arthralgia  | 24.6  | 0.7             | Very common           |
| Pain in extremity   | 10.0  | 0.2             | Very common           |
| <b>Nervous system disorders</b>                                 |   |                 |                       |
| Headache  | 21.8  | 0.4             | Very common           |
| Dysgeusia   | 22.7  | <0.1            | Very common           |
| Neuropathy peripheral   | 14.7  | 0.7             | Very common           |
| Dizziness   | 11.2  | 0.1             | Very common           |
| Peripheral sensory neuropathy                                   | 15.7  | 0.5             | Very common           |
| Paraesthesia  | 10.2  | 0.4             | Very common           |
| <b>Psychiatric disorders</b>                                    |   |                 |                       |
| Insomnia  | 15.9  | 0.2             | Very common           |

| ADR<br>(MedDRA Preferred Term)                         | Perjeta<br>+ trastuzumab<br>+ chemotherapy <sup>^^</sup> |                 | Frequency<br>category |
|--|--|-----------------|-----------------------|
|  | n = 3344 <sup>^^^</sup> (100%)                           |                 |                       |
| System Organ Class                                     | Frequency rate %   |                 |                       |
|  | All Grades<br>%  | Grades 3-4<br>% |                       |
| <b>Respiratory, thoracic and mediastinal disorders</b> |  |                 |                       |
| Cough  | 15.5   | <0.1            | Very common           |
| Dyspnoea   | 11.5   | 0.5             | Very common           |
| Pleural effusion                                       | 0.9  | <0.1            | Uncommon              |
| Epistaxis  | 15.6   | <0.1            | Very common           |
| <b>Skin and subcutaneous tissue disorders</b>          |  |                 |                       |
| Alopecia   | 63.1   | <0.1            | Very common           |
| Rash   | 26.4   | 0.5             | Very common           |
| Nail disorder  | 12.9   | 0.3             | Very common           |
| Pruritus   | 12.9   | <0.1            | Very common           |
| Dry skin   | 11.7   | <0.1            | Very common           |
| <b>Vascular disorders</b>                              |  |                 |                       |
| Hot flush  | 15.7   | 0.1             | Very common           |

<sup>^</sup> Table 3 shows pooled data from the overall treatment period in CLEOPATRA (data cutoff 11 February 2014; median number of cycles of Perjeta was 24); and from the neoadjuvant treatment period in NEOSPHERE (median number of cycles of Perjeta was 4, across all treatment arms) and TRYPHAENA (median number of cycles of Perjeta was 3 in the FEC/Ptz+T+D arm and 6 in the Ptz+T+FEC/Ptz+T+D and Ptz+TCH arms); and from the treatment period of APHINITY (median number of cycles of Perjeta was 18).

<sup>^^</sup> In NEOSPHERE, 108 patients received Perjeta + trastuzumab alone without docetaxel and 94 patients received Perjeta + docetaxel without trastuzumab.

<sup>^^^</sup> In CLEOPATRA, 45 patients who were randomised to receive placebo and who had no prior exposure to Perjeta, had crossed over to receive Perjeta and are included in the 980 patients treated with Perjeta.

\* In this table this denotes an adverse reaction that has been reported in association with a fatal outcome.

\*\* The incidence of left ventricular dysfunction and cardiac failure congestive reflect the MedDRA Preferred Terms reported in the individual studies.

### ***Further information on selected adverse drug reactions***

#### **Cardiac failure and left ventricular dysfunction**

In NEOSPHERE, in which patients received four cycles of Perjeta as neoadjuvant treatment, the incidence of LVD (during the overall treatment period) was higher in the Perjeta, trastuzumab and docetaxel-treated group (8.4%) compared to the trastuzumab and docetaxel-treated group (1.9%). There was one case of symptomatic LVD in the Perjeta and trastuzumab-treated group. In NEOSPHERE there was no central review of cardiac imaging results (see 4.4 Special warnings and precautions for use).

In TRYPHAENA, the incidence of LVD (during the overall treatment period) was 6.9% in the group treated with Perjeta plus trastuzumab and 5-fluorouracil, epirubicin and cyclophosphamide (FEC) followed by Perjeta plus trastuzumab and docetaxel; 16.0% in the group treated with Perjeta plus trastuzumab and docetaxel following FEC; and 10.5% in the

group treated with Perjeta in combination with TCH. The incidence of symptomatic LVD (congestive heart failure) was 1.3% in the group treated with Perjeta plus trastuzumab and docetaxel following FEC (this excludes a patient that experienced symptomatic LVD during FEC treatment prior to receiving Perjeta plus trastuzumab and docetaxel) and also 1.3% in the group treated with Perjeta in combination with TCH. No patients in the group treated with Perjeta plus trastuzumab and FEC followed by Perjeta plus trastuzumab and docetaxel experienced symptomatic LVD. In TRYPHAENA there was no central review of cardiac imaging results (see 4.4 Special warnings and precautions for use).

In the neoadjuvant period of the BERENICE trial, the incidence of NYHA Class III/IV symptomatic LVD (congestive heart failure according to NCI-CTCAE v.4) was 1.5% in the group treated with dose dense AC followed by Perjeta plus trastuzumab and paclitaxel and none of the patients (0%) experienced symptomatic LVD in the group treated with FEC followed by Perjeta in combination with trastuzumab and docetaxel. The incidence of asymptomatic LVD (PT ejection fraction decrease according to NCI-CTCAE v.4) was 7% in the group treated with dose dense AC followed by Perjeta plus trastuzumab and paclitaxel and 3.5% in the group treated with FEC followed by Perjeta plus trastuzumab and docetaxel.

In the pivotal trial CLEOPATRA, the incidence of LVD during study treatment was higher in the placebo- treated group than the Perjeta treated group (8.6% and 6.6%, respectively). The incidence of symptomatic LVD was also lower in the PERJETA treated group (1.8% in the placebo- treated group vs. 1.5% in the Perjeta treated group) (see 4.4 Special warnings and precautions for use).

In APHINITY, the incidence of symptomatic heart failure (NYHA class III or IV) with a LVEF decline of at least 10%-points from baseline and to <50% was <1% (0.6% of Perjeta-treated patients vs 0.2% of placebo-treated patients). Of the patients who experienced symptomatic heart failure, 46.7% of Perjeta-treated patients and 66.8% of placebo-treated patients had recovered (defined as 2 consecutive LVEF measurements above 50%) at the data cutoff. The majority of the events were reported in anthracycline-treated patients. Asymptomatic or mildly symptomatic (NYHA class II) declines in LVEF of at least 10%-points from baseline and to <50% were reported in 2.7% of Perjeta-treated patients and 2.8% of placebo-treated patients, of whom 79.7% of Perjeta-treated patients and 80.6% of placebo-treated patients had recovered at the data cutoff.

### Infusion related reactions

An infusion related reaction was defined in the pivotal trial as any event reported as hypersensitivity, anaphylactic reaction, acute infusion reaction or cytokine release syndrome occurring during an infusion, or on the same day as the infusion. In the pivotal trial CLEOPATRA, the initial dose of Perjeta was given the day before trastuzumab and docetaxel to allow for the examination of Perjeta associated reactions. On the first day, when only Perjeta was administered, the overall frequency of infusion related reactions was 9.8% in the placebo treated group and 13.2% in the Perjeta treated group, with the majority of reactions being mild or moderate. The most common infusion related reactions ( $\geq 1.0\%$ ) in the Perjeta treated group were pyrexia, chills, fatigue, headache, asthenia, hypersensitivity and vomiting.

During the second cycle, when all drugs were administered on the same day, the most common infusion related reactions ( $\geq 1.0\%$ ) in the Perjeta treated group were fatigue, drug hypersensitivity, dysgeusia, hypersensitivity, myalgia and vomiting (see 4.4 Special warnings and precautions for use).

In neoadjuvant and adjuvant trials, Perjeta was administered on the same day as the other study treatment drugs. Infusion-related reactions occurred in 18.6% - 25.0% of patients on the first day of Perjeta administration (in combination with trastuzumab and chemotherapy). The type and severity of events were consistent with those observed in CLEOPATRA, with a majority of reactions being mild or moderate.

#### Hypersensitivity reactions/anaphylaxis

In the pivotal trial CLEOPATRA, the overall frequency of hypersensitivity/anaphylaxis reported events was 9.1% in the placebo treated patients and 11.0% in the Perjeta treated patients, of which 2.5% and 2% were NCI-CTCAE (version 3) grade 3-4, respectively. Overall, 2 patients in placebo treated group and 4 patients in the Perjeta treated group experienced anaphylaxis (see (see 4.4 Special warnings and precautions for use).

Overall, the majority of hypersensitivity reactions were mild or moderate in severity and resolved upon treatment. Based on modifications made to study treatment, most reactions were assessed as secondary to docetaxel infusions.

In neoadjuvant and adjuvant trials, hypersensitivity/anaphylaxis events were consistent with those observed in CLEOPATRA. In NEOSPHERE, two patients in the Perjeta and docetaxel treated group experienced anaphylaxis. In both TRYPHAENA and APHINITY, the overall frequency of hypersensitivity/anaphylaxis was highest in the Perjeta and TCH treated group (13.2% and 7.6%, respectively), of which 2.6% and 1.3% of events, respectively, were NCI-CTCAE grade 3-4.

#### ***Laboratory Abnormalities***

In the pivotal trials CLEOPATRA, NEOSPHERE AND APHINITY the incidence of NCI-CTCAE grade 3-4 decreases in neutrophil counts were balanced in the Perjeta-treated and control groups.

#### **Post marketing Experience**

The following adverse drug reaction has been identified from post marketing experience with Perjeta based on spontaneous case reports and literature cases. The adverse drug reaction is listed according to system organ class in MedDRA.

**Table 4: Adverse Drug Reactions from Post marketing Experience**

| <b>System Organ Class</b>          | <b>Adverse reaction</b> |
|------------------------------------|-------------------------|
| Metabolism and nutrition disorders | Tumour Lysis Syndrome   |

#### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions <https://nzphvc.otago.ac.nz/reporting/>

#### **4.9 Overdose**

There is no experience with overdosage in human clinical trials. Single doses higher than 25 mg/kg (1727 mg) have not been tested.

Treatment of overdose should consist of general supportive measures.

For information on the management of overdose, contact the Poison Information Centre (in Australia call 13 11 26; in New Zealand call 0800 764 766).

## 5. PHARMACOLOGICAL PROPERTIES

### 5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antineoplastic agents, monoclonal antibodies, ATC code: L01XC13

#### Mechanism of Action

Pertuzumab binds to the extracellular dimerization domain (Subdomain II) of the human epidermal growth factor receptor 2 protein (HER2) and thereby blocks ligand-dependent heterodimerization of HER2 with other HER family members, including EGFR, HER3 and HER4. It inhibits ligand initiated intracellular signalling through two major signal pathways, mitogen activated protein (MAP) kinase and phosphoinositide 3 kinase (PI3K). Inhibition of these signalling pathways can result in cell growth arrest and apoptosis, respectively. In addition, pertuzumab mediates antibody-dependent cell-mediated cytotoxicity (ADCC). While pertuzumab alone inhibited the proliferation of human tumour cells, the anti-tumour activity was significantly augmented when pertuzumab was used in combination with trastuzumab in HER2-overexpressing xenograft models.

#### Clinical trials

HER2 overexpression was determined at a central laboratory and defined as a score of 3+ by IHC or an ISH amplification ratio  $\geq 2.0$  in the trials outlined below.

#### *Early Breast Cancer*

##### NEOSPHERE (WO20697)

NEOSPHERE is a Phase II, multinational randomised controlled trial with Perjeta and was conducted in 417 adult female patients with newly diagnosed, early inflammatory or locally advanced HER2-positive breast cancer (T2-4d, primary tumour > 2cm in diameter) who had not received prior trastuzumab, chemotherapy or radiotherapy. Patients with metastases, bilateral breast cancer, clinically important cardiac risk factors (see 4.4 Special warnings and precautions for use) or LEVF < 55% were not included. The majority of patients were less than 65 years old.

Patients were randomised to receive one of the following neoadjuvant regimens for 4 cycles prior to surgery:

- trastuzumab plus docetaxel
- Perjeta plus trastuzumab and docetaxel
- Perjeta plus trastuzumab
- Perjeta plus docetaxel

Randomisation was stratified by breast cancer type (operable, locally advanced, or inflammatory) and oestrogen (ER) or progesterone (PgR) positivity.

Perjeta and trastuzumab were administered intravenously for 4 cycles (see 4.2 Dose and Method of Administration). Following surgery all patients received three cycles of 5-Fluorouracil (600 mg/m<sup>2</sup>), epirubicin (90 mg/m<sup>2</sup>), cyclophosphamide (600 mg/m<sup>2</sup>) (FEC) given intravenously every three weeks and trastuzumab administered intravenously every three weeks to complete one year of therapy. Patients in the Perjeta plus trastuzumab and docetaxel arm received docetaxel every three weeks for four cycles prior to FEC after surgery so that all patients received equivalent cumulative doses of the chemotherapeutic agents and trastuzumab.

The primary endpoint of the study was pathological complete response (pCR) rate in the breast (ypT0/is). Secondary efficacy endpoints were clinical response rate, breast conserving surgery rate (T2-3 only), disease-free survival (DFS), and PFS. Additional exploratory pCR rates included nodal status (ypT0/isN0 and ypT0N0).

Demographics were well balanced (median age was 49-50 years old, the majority were Caucasian (71%) and all were female. Overall 7% of patients had inflammatory breast cancer, 32% had locally advanced breast cancer and 61% had operable breast cancer. Approximately half the patients in each treatment group had hormone receptor-positive disease (defined as ER positive and/or PgR positive).

The efficacy results are summarised in Table 5. A statistically significant and clinically meaningful improvement in pCR rate (ypT0/is) was observed in patients receiving Perjeta plus trastuzumab and docetaxel compared to patients receiving trastuzumab and docetaxel (45.8% vs 29.0%, p value = 0.0141). A consistent pattern of results was observed regardless of pCR definition.

The pCR rates as well as the magnitude of benefit with Perjeta (for patients receiving Perjeta plus trastuzumab and docetaxel compared with trastuzumab and docetaxel) were lower in the subgroup of patients with hormone receptor-positive tumours than in patients with hormone receptor-negative tumours (difference of 6% in pCR in the breast) than patients with hormone receptor-negative tumours (difference of 26.4% in pCR in the breast).. pCR rates were similar in patients with operable versus locally advanced disease. There were too few patients with inflammatory breast cancer to draw any firm conclusions but the pCR rate was higher in patients who received Perjeta plus trastuzumab and docetaxel.

#### TRYPHAENA (BO22280)

TRYPHAENA is a multicenter, randomised Phase II clinical study conducted in 225 patients with HER2-positive locally advanced, operable, or inflammatory (T2-4d) breast cancer.

Patients were randomised to receive one of three neoadjuvant regimens prior to surgery as follows:

- 3 cycles of FEC followed by 3 cycles of docetaxel all in combination with Perjeta and trastuzumab,
- 3 cycles of FEC alone followed by 3 cycles of docetaxel and trastuzumab in combination with Perjeta or
- 6 cycles of TCH in combination with Perjeta

There is insufficient evidence to recommend concomitant administration of an anthracycline with Perjeta.

Randomisation was stratified by breast cancer type (operable, locally advanced, or inflammatory) and ER and /or PgR positivity.

Perjeta and trastuzumab were administered intravenously as outlined in 4.2 Dose and Method of Administration. 5-Fluorouracil (500 mg/m<sup>2</sup>), epirubicin (100 mg/m<sup>2</sup>), cyclophosphamide (600 mg/m<sup>2</sup>) were given intravenously every three weeks for 3 cycles. Docetaxel was given as an initial dose of 75 mg/m<sup>2</sup> IV infusion every three weeks with the option to escalate to 100 mg/m<sup>2</sup> at the investigator's discretion if the initial dose was well tolerated. However, in the Perjeta in combination with TCH arm, docetaxel was given intravenously at 75 mg/m<sup>2</sup> and no escalation was permitted and carboplatin (AUC 6) was given intravenously every three weeks. Following surgery all patients received trastuzumab to complete one year of therapy, which was administered intravenously every 3 weeks.

The primary endpoint of this study was cardiac safety during the neoadjuvant treatment period of the study. Secondary efficacy endpoints were pCR rate in the breast (ypT0/is), DFS, PFS and OS.

Demographics were well balanced (median age was 49-50 years old, the majority were Caucasian (77%) and all were female. Overall 6% of patients had inflammatory breast cancer, 25% had locally advanced breast cancer and 69% had operable breast cancer, with approximately half the patients in each treatment group had ER-positive and/or PgR-positive disease.

pCR rates were observed in all 3 treatment arms (see Table 5). A consistent pattern of results was observed regardless of pCR definition. pCR rates were lower in the subgroup of patients with hormone receptor-positive tumours than in patients with hormone receptor-negative tumours (46.2% to 50.0% and 65.0% to 83.8% respectively).

**Table 5: NEOSPHERE (WO20697) and TRYPHAENA (BO22280): Summary of Efficacy (ITT population)**

| Parameter  | NEOSPHERE (WO20697)        |                            |                            |                            | TRYPHAENA (BO22280)           |                            |                            |
|--|----------------------------|----------------------------|----------------------------|----------------------------|-------------------------------|----------------------------|----------------------------|
|  | T+D<br>N=107               | Ptz+T+D<br>N=107           | Ptz+T<br>N=107             | Ptz+D<br>N=96              | Ptz+T+FEC/<br>Ptz+T+D<br>N=73 | FEC/<br>Ptz+T+D<br>N=75    | Ptz+TCH<br>N=77            |
| ypT0/is N0<br>n (%)<br>[95% CI]                                  | 23 (21.5%)<br>[14.1; 30.5] | 42 (39.3%)<br>[30.3; 49.2] | 12 (11.2%)<br>[5.9; 18.8]  | 17 (17.7%)<br>[10.7; 26.8] | 41 (56.2%)<br>[44.1; 67.8]    | 41 (54.7%)<br>[42.7; 66.2] | 49 (63.6%)<br>[51.9; 74.3] |
| ypT0/is<br>n (%)<br>[95% CI] <sup>1</sup>                        | 31 (29.0%)<br>[20.6; 38.5] | 49 (45.8%)<br>[36.1; 55.7] | 18 (16.8%)<br>[10.3; 25.3] | 23 (24.0%)<br>[15.8; 33.7] | 45 (61.6%)<br>[49.5; 72.8]    | 43 (57.3%)<br>[45.4; 68.7] | 51 (66.2%)<br>[54.6; 76.6] |
| Difference in pCR<br>rates <sup>2</sup><br>[95% CI] <sup>3</sup> |                            | +16.8 %<br>[3.5; 30.1]     | -12.2 %<br>[-23.8; -0.5]   | -21.8 %<br>[-35.1; -8.5]   | NA                            | NA                         | NA                         |
| p-value (with Simes<br>corr. for CMH test) <sup>4</sup>          |                            | 0.0141<br>(vs. T+D)        | 0.0198<br>(vs. T+D)        | 0.0030<br>(vs Ptz+T+D)     | NA                            | NA                         | NA                         |



|                                |             |              |             |             |              |              |              |
|--------------------------------|-------------|--------------|-------------|-------------|--------------|--------------|--------------|
| ypT0 N0<br>n (%)               | 13 (12.1%)  | 35 (32.7%)   | 6 (5.6)     | 13 (13.2%)  | 37 (50.7%)   | 34 (45.3%)   | 40 (51.9%)   |
| [95% CI]                       | [6.6; 19.9] | [24.0; 42.5] | [2.1; 11.8] | [7.4; 22.0] | [38.7; 62.6] | [33.8; 57.3] | [40.3; 63.5] |
| Clinical Response <sup>5</sup> | 79 (79.8%)  | 89 (88.1%)   | 69 (67.6%)  | 65 (71.4%)  | 67 (91.8%)   | 71 (94.7%)   | 69 (89.6%)   |

**Key to abbreviations:** T: trastuzumab; D: docetaxel; Ptz: Perjeta; FEC: 5-fluorouracil, epirubicin, cyclophosphamide; TCH: docetaxel, carboplatin and trastuzumab.

1. 95% CI for one sample binomial using Pearson-Clopper method.
2. Treatment Ptz+T+D and Ptz+T are compared with T+D, while Ptz+D is compared with Ptz+T+D
3. Approximate 95% CI for difference of two rates using Hauck-Anderson method.
4. p-value from Cochran-Mantel-Haenszel test, with Simes multiplicity adjustment
5. Clinical response represents patients with a best overall response of CR or PR during the neoadjuvant period (in the primary breast lesion)

### BERENICE (WO29217)

BERENICE is a non-randomised, open-label, multicenter, multinational, Phase II trial conducted in 401 patients with HER2-positive locally advanced, inflammatory, or early-stage HER2-positive breast cancer.

The BERENICE study included two parallel groups of patients. Patients considered suitable for neoadjuvant treatment with trastuzumab plus anthracycline/taxane-based chemotherapy were allocated to receive one of the two following regimens prior to surgery as follows:

Cohort A - 4 cycles of two weekly doxorubicin and cyclophosphamide (dose dense AC) followed by 4 cycles of Perjeta in combination with trastuzumab and paclitaxel

Cohort B - 4 cycles of FEC followed by 4 cycles of Perjeta in combination with trastuzumab and docetaxel.

Perjeta and trastuzumab were administered intravenously as outlined in 4.2 Dose and Method of Administration. Doxorubicin 60 mg/m<sup>2</sup> IV and cyclophosphamide 600 mg/m<sup>2</sup> IV were administered every 2 weeks (ddAC) for four cycles (Cycles 1-4) with G-CSF (granulocyte colony stimulating factor) support at investigator discretion, followed by paclitaxel 80 mg/m<sup>2</sup> IV weekly for 12 weeks (Cycles 5-8), with Perjeta and trastuzumab every 3 weeks during Cycles 5-8 (from the start of paclitaxel; four cycles of Perjeta and trastuzumab in total during the neoadjuvant period). 5-Fluorouracil (500 mg/m<sup>2</sup>), epirubicin (100 mg/m<sup>2</sup>), cyclophosphamide (600 mg/m<sup>2</sup>) were given intravenously every three weeks for 4 cycles. Docetaxel was given at an initial dose of 75 mg/m<sup>2</sup> IV infusion every three weeks with the option to escalate to 100 mg/m<sup>2</sup> at the investigator's discretion if the initial dose was well tolerated. Following surgery all patients received Perjeta and trastuzumab which were administered intravenously every 3 weeks, to complete one year of therapy.

The primary endpoint of this study was cardiac safety during the neoadjuvant treatment period of the study (see 4.8 Undesirable effects). Key secondary endpoints at the time of primary analysis were neoadjuvant safety and pCR rate in the breast and nodes (i.e. ypT0/is ypN0). Long-term clinical and safety outcomes will also be assessed (IDFS, EFS and OS, not yet available).

Demographics of the patients were well balanced between the groups.. The median age of the patients was 49 years, the majority of patients were Caucasian (83%) and all but one patient

was female. Approximately two-thirds of patients (64.3% [n=128] in Cohort A and 61.7% [n=124] in Cohort B) had hormone receptor-positive disease.

High pCR rates were observed in both treatment arms, with pCR (ypT0/is ypN0) rates of 61.8% in Cohort A and 60.7% in Cohort B. A consistent pattern of results was observed regardless of pCR definition. pCR rates were lower in the subgroup of patients with hormone receptor-positive tumors than in patients with hormone receptor-negative tumors in both Cohorts (51.6% to 81.5% and 57.3% to 68.0% respectively).

#### APHINITY (BO25126)

APHINITY is a multicentre, randomised, double-blind, placebo-controlled Phase III trial conducted in 4804 patients with HER2-positive early breast cancer who had their primary tumor excised prior to randomisation. Patients were then randomised to receive Perjeta or placebo, in combination with adjuvant trastuzumab and chemotherapy. Investigators selected one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens for individual patients:

- 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel
- 4 cycles of AC or EC, followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel
- 6 cycles of docetaxel in combination with carboplatin

Perjeta and trastuzumab were administered intravenously (see Section 4.2 Dose and Method of Administration) every 3 weeks starting on Day 1 of the first taxane-containing cycle, for a total of 52 weeks (maximum 18 cycles) or until recurrence, withdrawal of consent or unmanageable toxicity. Standard doses of 5-fluorouracil, epirubicin, doxorubicin, cyclophosphamide, docetaxel, paclitaxel and carboplatin were administered. After completion of chemotherapy, patients received radiotherapy and/or hormone therapy as per local clinical standard.

The primary endpoint of the study was invasive disease-free survival (IDFS), defined as the time from randomisation to first occurrence of ipsilateral local or regional invasive breast cancer recurrence, distant recurrence, contralateral invasive breast cancer, or death from any cause.

Demographics were well balanced between the two treatment arms. The median age was 51 years, and over 99% of patients were female. The majority of patients had node-positive (63%) and/or hormone receptor-positive disease (64%), and were Caucasian (71%).

After a median follow-up to 45.4 months, the APHINITY study demonstrated 19% (hazard ratio [HR] = 0.81) reduction in risk of recurrence or death in patients randomised to receive Perjeta compared with patients randomised to receive placebo.

The efficacy results from the APHINITY trial are summarised in Table 6 and in Figures 1 and 2.

**Table 6: Overall Efficacy (ITT Population)**

|  | <b>Perjeta +<br/>trastuzumab +<br/>chemotherapy<br/>n=2400</b> | <b>Placebo +<br/>trastuzumab +<br/>chemotherapy<br/>n=2404</b> |
|--|--|--|
| <b>Primary Endpoint</b>                                |  |  |
| <b>Invasive Disease Free Survival (IDFS)</b>           |  |  |
| Number (%) of patients with event                      | 171 (7.1%)   | 210 (8.7%)   |
| HR [95% CI]  | 0.81 [0.66, 1.00]  |  |
| p-value (Log-Rank test, stratified <sup>2</sup> )      | 0.0446   |  |
| 3 year event-free rate <sup>3</sup> [95% CI]           | 94.1 [93.1, 95.0]  | 93.2 [92.2, 94.3]  |
| <b>Secondary Endpoints<sup>1</sup></b>                 |  |  |
| <b>IDFS including second primary non-breast cancer</b> |  |  |
| Number (%) of patients with event                      | 189 (7.9%)   | 230 (9.6%)   |
| HR [95% CI]  | 0.82 [0.68, 0.99]  |  |
| p-value (Log-Rank test, stratified <sup>2</sup> )      | 0.0430   |  |
| 3 year event-free rate <sup>3</sup> [95% CI]           | 93.5 [92.5, 94.5]  | 92.5 [91.4, 93.6]  |
| <b>Disease Free Survival (DFS)</b>                     |  |  |
| Number (%) of patients with event                      | 192 (8.0%)   | 236 (9.8%)   |
| HR [95% CI]  | 0.81 [0.67, 0.98]  |  |
| p-value (Log-Rank test, stratified <sup>2</sup> )      | 0.0327   |  |
| 3 year event-free rate <sup>3</sup> [95% CI]           | 93.4 [92.4, 94.4]  | 92.3 [91.2, 93.4]  |
| <b>Overall Survival (OS)<sup>4</sup></b>               |  |  |
| Number (%) of patients with event                      | 80 (3.3%)  | 89 (3.7%)  |
| HR [95% CI]  | 0.89 [0.66, 1.21]  |  |
| p-value (Log-Rank test, stratified <sup>2</sup> )      | 0.4673   |  |
| 3 year event-free rate <sup>3</sup> [95% CI]           | 97.7 [97.0, 98.3]  | 97.7 [97.1, 98.3]  |
| <b>Recurrence Free Interval (RFI)</b>                  |  |  |
| Number (%) of patients with event                      | 138 (5.8%)   | 173 (7.2%)   |
| HR [95% CI]  | 0.79 [0.63, 0.99]  |  |
| p-value (Log-Rank test, stratified <sup>2</sup> )      | 0.0430   |  |
| 3 year event-free rate <sup>3</sup> [95% CI]           | 95.2 [94.3, 96.1]  | 94.3 [93.3, 95.2]  |
| <b>Distant recurrence-free interval (DRFI)</b>         |  |  |
| Number (%) of patients with event                      | 119 (5.0%)   | 145 (6.0%)   |
| HR [95% CI]  | 0.82 [0.64, 1.04]  |  |
| p-value (Log-Rank test, stratified <sup>2</sup> )      | 0.1007   |  |
| 3 year event-free rate <sup>3</sup> [95% CI]           | 95.7 [94.9, 96.5]  | 95.1 [94.3, 96.0]  |

Key to abbreviations: ITT: Intent-to-treat; HR: Hazard Ratio; CI: Confidence Intervals,


1. Hierarchical testing applied for all secondary endpoints with the exception of RFI and DRFI.

2. All analyses stratified by nodal status, protocol version, central hormone receptor status, and adjuvant chemotherapy regimen.

3. 3-year event-free rate derived from Kaplan-Meier estimates

#### 4. Data from first interim analysis

**Figure 1: Kaplan-Meier curve of invasive disease free survival**




Pla = placebo; Ptz = Perjeta; T = trastuzumab

The estimate of IDFS at 4-years was 92.3% in the Perjeta-treated group versus 90.6% in the placebo-treated group. At the time of the estimate the median follow-up was 45.4 months.

#### *Results of Subgroup Analysis*

Consistent results were observed across the majority of pre-specified patient subgroups. The benefits of Perjeta were more apparent for patients in certain high risk groups, notably patients with node-positive or hormone receptor-negative disease.

**Figure 2: Forest plot of invasive disease free survival by subgroup**



Pla = placebo; Ptz = Perjeta; T = trastuzumab

Estimates of IDFS rates in the node positive subgroup were 92.0% versus 90.2% at 3 years and 89.9% vs. 86.7% at 4 years in Perjeta-treated patients versus the placebo-treated patients, respectively. In the node negative subgroup estimates of IDFS rates were 97.5% versus 98.4% at 3 years and 96.2% versus 96.7% at 4 years in Perjeta-treated patients versus placebo-treated patients, respectively. In the hormone receptor-positive subgroup estimates of IDFS were 94.8% versus 94.4% at 3 years and 93.0% versus 91.6% at 4 years in Perjeta-treated patients versus placebo-treated patients, respectively. In the hormone receptor-negative subgroup estimates of IDFS rates were 92.8% versus 91.2% at 3 years and 91.0% versus 88.7% at 4 years in Perjeta-treated patients versus placebo-treated patients, respectively.

### Patient Reported Outcomes (PRO)

Secondary endpoints included the assessment of patient-reported global health status, role and physical function, and treatment symptoms using the EORTC QLQ-C30 and EORTC QLQ-BR23 questionnaires. In the analyses of patient-reported outcomes, a 10-point difference was considered clinically meaningful.

Patients' physical function, global health status and diarrhoea scores showed a clinically meaningful change during chemotherapy in both treatment arms. The mean decrease from baseline at that time for physical function was -10.7 (95% CI -11.4, -10.0) in the Perjeta arm and -10.6 (95% -11.4, -9.9) in the placebo arm; global health status was -11.2 (95% CI -12.2, -10.2) in the Perjeta arm and -10.2 (95% CI -11.1, -9.2) in the placebo arm. Change in diarrhoea symptoms increased to +22.3 (95% CI 21.0, 23.6) in the Perjeta arm versus +9.2 (95% CI 8.2, 10.2) in the placebo arm.

Thereafter in both arms, physical function and global health status scores returned to baseline levels during targeted treatment. Diarrhoea symptoms returned to baseline after HER2 therapy in the Perjeta-arm. The addition of Perjeta to trastuzumab plus chemotherapy did not affect patients' overall role function over the course of the study.

### ***Metastatic Breast Cancer***

#### ***Perjeta in combination with trastuzumab and docetaxel***

##### WO20698/TOC4129g (CLEOPATRA)

CLEOPATRA is a multicentre, randomised, double-blind, placebo-controlled phase III clinical trial conducted in 808 patients with HER2-positive metastatic (n=789) or locally recurrent unresectable breast cancer (n=19) who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. Patients were randomised 1:1 to receive placebo + trastuzumab and docetaxel or Perjeta + trastuzumab and docetaxel. Randomisation was stratified by prior treatment status (de novo or prior adjuvant/neoadjuvant therapy) and geographic region (Europe, North America, South America and Asia). Patients with prior adjuvant or neoadjuvant therapy were required to have a disease free interval of at least 12 months before enrolment into the trial.

Perjeta and trastuzumab were administered intravenously as outlined in 4.2 Dose and Method of Administration. Patients were treated with Perjeta and trastuzumab until disease progression, withdrawal of consent or unmanageable toxicity. Docetaxel was given as an initial dose of 75 mg/m<sup>2</sup> IV infusion every 3 weeks for at least 6 cycles. The dose of docetaxel could be escalated to 100 mg/m<sup>2</sup> at the investigator's discretion if the initial dose was well tolerated.

At the time of the primary analysis, the mean number of cycles of study treatment received was 16.2 in the placebo treatment group and 19.9 in the Perjeta treated group.

The primary endpoint of the study was progression-free survival (PFS) as assessed by an independent review facility (IRF) and defined as the time from the date of randomisation to the date of disease progression or death (from any cause) if the death occurred within 18 weeks of the last tumour assessment. Secondary efficacy endpoints were overall survival (OS), PFS (investigator-assessed), objective response rate (ORR), duration of response, and time to symptom progression according to the FACT-B QoL (Functional Assessment of Cancer Therapy–Breast, Quality of Life) questionnaire.

Demographics were well balanced (median age was 54 years old, majority Caucasian (59%) and all were female with the exception of 2 patients). Approximately half the patients in each treatment group had hormone receptor-positive disease (defined as oestrogen receptor positive and/or progesterone receptor positive), approximately half of the patients in each treatment group had received prior adjuvant or neoadjuvant therapy (192 patients [47.3%] in the placebo treated group vs. 184 patients [45.8%] in the Perjeta treated group), and approximately 11% of patients had received prior trastuzumab (41 patients [10.1%] in the placebo treated group vs. 47 patients [11.7%] in the Perjeta treated group). Of the 19 patients categorized as having locally recurrent, unresectable disease, 6 patients (2 in the placebo group and 4 in the Perjeta group) had metastases on their baseline assessment.

At the time of the primary PFS analysis, a total of 242 patients (59%) in the placebo treated group and 191 patients (47.5%) in the Perjeta treated group had IRF-confirmed progressive disease or had died within 18 weeks of their last tumour assessment.

At the time of the primary analysis, the CLEOPATRA study demonstrated a statistically significant improvement in IRF-assessed PFS (hazard ratio [HR] = 0.62, 95% CI = 0.51, 0.75,  $p < 0.0001$ ) in the Perjeta treated group compared with the placebo treated group, and an increase in median PFS of 6.1 months (median PFS of 12.4 months in the placebo treated group vs. 18.5 months in the Perjeta treated group) (see Figure 3). At the time of the primary analysis, the results for investigator-assessed PFS were comparable to those observed for IRF-assessed PFS (median PFS was 12.4 months for placebo vs. 18.5 months for Perjeta) (see Table 7). Consistent results were observed across pre-specified patient subgroups including the subgroups based on stratification factors of geographic region and prior adjuvant/neoadjuvant therapy or de novo metastatic breast cancer (see Figure 4).

The efficacy results from the CLEOPATRA trial are summarized in Table 7 below.


**Table 7: Summary of efficacy from CLEOPATRA study**

| Parameter   | Placebo<br>+ trastuzumab<br>+ docetaxel<br>(n=406) | Perjeta<br>+ trastuzumab<br>+ docetaxel<br>(n=402) | HR<br>(95% CI)                                | p-value |
|---|--|--|---|---------|
| <b>Primary Endpoint:</b>  |  |  |   |         |
| <b>Progression-Free Survival<br/>(Independent review facility<br/>assessment) – primary<br/>endpoint*</b> |  |  | 0.62<br>[0.51;0.75]                           | <0.0001 |
| No. of patients with an event   | 242 (59%)  | 191 (47.5%)  |   |         |
| Median months   | 12.4   | 18.5   |   |         |
| <b>Secondary Endpoints:</b>   |  |  |   |         |
| <b>Overall Survival (final<br/>analysis of OS)**</b>  |  |  | 0.68<br>[0.56;0.84]                           | 0.0002  |
| No. of patients with an event   | 221 (54.4%)  | 168 (41.8)   |   |         |
| Median months   | 40.8   | 56.5   |   |         |
| <b>Progression-Free Survival<br/>(investigator assessment)</b>  |  |  | 0.65<br>[0.54;0.78]                           | <0.0001 |
| No. of patients with an event   | 250 (61.6%)  | 201 (50.0%)  |   |         |
| Median months   | 12.4   | 18.5   |   |         |
| <b>Objective Response Rate<br/>(ORR)</b>  |  |  | Difference<br>in ORR:<br>10.8%<br>[4.2,17.5]% | 0.0011  |
| No. of patients with an event   | 336  | 343  |   |         |
| Responders***   | 233 (69.3 %)                                       | 275 (80.2 %)                                       |   |         |
| 95% CI for ORR  | [64.1; 74.2]                                       | [75.6; 84.3]                                       |   |         |
| Complete response (CR)  | 14 (4.2 %)   | 19 (5.5 %)   |   |         |
| Partial Response (PR)   | 219 (65.2 %)                                       | 256 (74.6 %)                                       |   |         |
| Stable disease (SD)   | 70 (20.8 %)  | 50 (14.6 %)  |   |         |
| Progressive disease (PD)  | 28 (8.3 %)   | 13 (3.8 %)   |   |         |
| <b>Duration of Response ^#</b>  |  |  |   |         |
| n=  | 233  | 275  |   |         |
| Median weeks  | 54.1   | 87.6   |   |         |

| Parameter         | Placebo<br>+ trastuzumab<br>+ docetaxel<br>(n=406) | Perjeta<br>+ trastuzumab<br>+ docetaxel<br>(n=402) | HR<br>(95% CI) | p-value |
|-------------------|--|--|----------------|---------|
| 95% CI for Median | [46;64]  | [71;106]   |                |         |


\* Primary progression-free survival analysis, cutoff date 13 May 2011  
 \*\* Final analysis of overall survival cutoff date 11 Feb 2014.  
 \*\*\* Patients with best overall response of confirmed CR or PR by RECIST.  
 ^ Evaluated in patients with best Overall Response of CR or PR  
 # Objective response rate and duration of response are based on IRF-assessed tumour assessments

**Figure 3: Kaplan-Meier curve of IRF-assessed progression-free survival**






**Figure 4: IRF assessed PFS by patient subgroup**



At the primary analysis of efficacy, an interim analysis of OS showed a strong trend suggestive of a survival benefit in favour of the Perjeta treated group.

The final analysis of OS was performed when 389 patients had died (221 in the Placebo-treated group and 168 in the Perjeta-treated group). The statistically significant OS benefit in favour of the Perjeta-treated group was maintained (HR 0.68,  $p = 0.0002$  log-rank test). The median time to death was 40.8 months in the placebo-treated group and 56.5 months in the Perjeta-treated group (see Table 7, Figure 5).

**Figure 5: Kaplan-Meier curve of overall survival**



There was no statistically significant difference between treatment groups in Health Related Quality of Life as assessed by time to symptom progression on the FACT-B TOI-PFB subscale, defined as a 5 point reduction in subscale score (HR =0.97, 95% CI =0.81; 1.16).

### ***Immunogenicity***

Patients in the pivotal trial CLEOPATRA were tested at multiple time-points for anti-drug antibodies (ADA) to Perjeta. 6.7% (25/372) of patients in the placebo treated group and 3.3% (13/389) of patients in the Perjeta treated group tested positive for ADA. In BERENICE, 4.1% (16/392) of the patients treated with Perjeta tested positive for ADA. None of these patients experienced anaphylactic/hypersensitivity reactions that were clearly related to ADA.

Immunogenicity assay results are highly dependent on several factors including assay sensitivity and specificity, assay methodology, sample handling, timing of sample collection, concomitant medications and underlying disease. For these reasons, comparison of incidence of antibodies to Perjeta with the incidence of antibodies to other products may be misleading.

## **5.2 Pharmacokinetic properties**

Across multiple clinical trials, in various indications, there was no change in clearance of pertuzumab at doses of 2-25 mg/kg. Based on a population PK analysis that included 444 patients, the median clearance (CL) of pertuzumab was 0.239 L/day and the median half-life was 17.2 days.

The population PK analysis suggested no PK differences based on age, gender and ethnicity (Japanese versus non-Japanese). Baseline albumin and lean body weight were the most significant covariates influencing CL. Clearance decreased in patients with higher baseline albumin concentrations and increased in patients with greater lean body weight. However, sensitivity analyses performed at the recommended dose and schedule of Perjeta showed that at the extreme values of these two covariates, there was no significant impact on the ability to achieve target steady-state concentrations identified in preclinical tumour xenograft models. Therefore, there is no need to adjust the dosage of pertuzumab based on these covariates.

The PK results of pertuzumab in the NEOSPHERE and APHINITY studies were consistent with the predictions from the previous population PK model. No differences in pertuzumab PK were observed in patients with early breast cancer compared to patients with metastatic breast cancer.

### **Absorption**

Pertuzumab is administered as an intravenous (IV) infusion.

### **Distribution**

Across all clinical studies, the volume of distribution of the central ( $V_c$ ) and the peripheral ( $V_p$ ) compartment in the typical patient, was 3.11L and 2.46L, respectively.

### **Metabolism**

The metabolism of pertuzumab has not been directly studied. Antibodies are cleared principally by catabolism.

### Excretion

The median clearance (CL) of pertuzumab was 0.235 L/day and the median half life was 18 days.

### Pharmacokinetics in Special Populations

#### *Elderly*

No dedicated pertuzumab studies have been conducted in elderly patients. In a population PK analysis, age was not found to significantly affect PK of pertuzumab. In the population PK analysis, 32.5% (n=143) patients were  $\geq 65$  years of age and 9.1% (n=40) patients were  $\geq 75$  years of age.

#### *Renal impairment*

No formal PK study has been conducted in patients with renal impairment. Based on the population PK analysis, renal impairment is not expected to influence pertuzumab exposure; however, only limited data from patients with moderate and severe renal impairment were included in the population PK analysis.

## **5.3 Preclinical safety data**

### ***Genotoxicity***

Studies have not been performed to evaluate the mutagenic potential of pertuzumab.

### ***Carcinogenicity***

Long-term studies in animals have not been performed to evaluate the carcinogenic potential of pertuzumab.

### ***Fertility***

No specific fertility studies in animals have been performed to evaluate the effect of Perjeta. No adverse effects on male and female reproductive organs were observed in repeat-dose toxicity studies of up to six month duration in cynomolgus monkeys.

### ***Other***

In cynomolgus monkeys, weekly IV administration of pertuzumab at doses up to 150 mg/kg/dose were generally well tolerated. With doses of 15 mg/kg and higher intermittent mild treatment-associated diarrhoea was noted. In a subset of monkeys chronic dosing (7 to 26 weekly doses) resulted in episodes of diarrhoea-related dehydration which were managed with IV fluid replacement therapy.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Sucrose, polysorbate 20, histidine and acetic acid - glacial.

### **6.2 Incompatibilities**

No incompatibilities between Perjeta and polyvinylchloride (PVC), polyethylene or non-PVC polyolefin bags have been observed.

Glucose (5%) solution should not be used to dilute Perjeta since it is chemically and physically unstable (diluted formulations of pertuzumab concentrate solution in Glucose (5%) IV bags did not maintain stable pH after storage at room temperature (27-33°C) for 24 hours followed by 24 hours at 2-8°C).

Perjeta should not be mixed or diluted with other drugs.

### **6.3 Shelf-life**

2 years.

Perjeta does not contain any anti-microbial preservative; therefore, care must be taken to ensure the sterility of the prepared solution.

The Perjeta infusion solution, diluted in PVC or non-PVC polyolefin bags, may be stored at 2°C–8°C for up to 24 hours prior to use. Diluted Perjeta has been shown to be stable for up to 24 hours (up to 30°C) however, since diluted Perjeta contains no preservative, the diluted solution should be refrigerated (2°C–8°C).

### **6.4 Special precautions for storage**

Store the vials in a refrigerator at 2 °C to 8 °C. Do not freeze.

Keep vial in the outer carton in order to protect from light. Do not shake.

This medicine should not be used after the expiry date (EXP) shown on the pack.

### **6.5 Nature and contents of container**

Single-use glass vial containing 14 mL of solution. Each vial contains 420 mg of pertuzumab (30 mg/mL).

### **6.6 Special precautions for disposal**

The release of medicines into the environment should be minimized. Medicines should not be disposed of via wastewater and disposal through household waste should be avoided. Unused or expired medicine should be returned to a pharmacy for disposal.

## **7. MEDICINE SCHEDULE**

Australia: Schedule 4 – Prescription Only Medicine.

New Zealand: Prescription.

## **8. SPONSOR**

Distributed in Australia by:  
Roche Products Pty Limited  
ABN 70 000 132 865  
Level 8, 30-34 Hickson Road  
Sydney NSW 2000  
AUSTRALIA  
Medical enquiries: 1800 233 950



Distributed in New Zealand by:  
Roche Products (New Zealand) Limited  
PO Box 109113, Newmarket, Auckland 1149  
NEW ZEALAND  
Medical enquiries: 0800 276 243

## **9. DATE OF FIRST APPROVAL**

18 July 2013

## **10. DATE OF REVISION OF THE TEXT**

21 November 2018

## **SUMMARY TABLE OF CHANGES**

| <b>Section Changed</b> | <b>Summary of new information</b>  |
|------------------------|--|
| 4.4                    | Safety update to “Infusion related reactions” and “Hypersensitivity reactions/anaphylaxis” |